Annovis Bio Business Summary

Annovis Bio, Inc. (ANVS) is a clinical-stage biopharmaceutical company that operates as a pre-revenue entity, currently generating no income from product sales. Its business model is centered on the research and development of a proprietary drug platform targeting neurodegenerative diseases, specifically Alzheimer’s (AD) and Parkinson’s (PD). The company operates through a single segment focused on its lead candidate, buntanetap (formerly ANVS401), which utilizes a unique translational mechanism to inhibit the synthesis of multiple neurotoxic proteins. Revenue generation is contingent upon future licensing agreements, milestone payments, or the commercialization of its pipeline following regulatory approval. Direct competitors include Biogen, Eli Lilly, and Cassava Sciences; Annovis positions itself as a differentiated player by targeting the underlying axonal transport dysfunction through a multi-protein approach rather than focusing solely on amyloid-beta or tau clearance. The company was founded by Dr. Maria L. Maccecchini, who serves as President and CEO and brings over 30 years of experience in neurodegeneration, including the successful sale of her previous venture, Symphony Pharmaceuticals, to Transgenomic. The executive team is further strengthened by Chief Financial Officer Mark Guerin and Chief Business Officer Mark White, a former Vice President at Pfizer with deep expertise in global pharmaceutical marketing and business development. Clinical and scientific strategy is overseen by Dr. Cheng Fang, Senior VP of Research and Development, and Senior VP of Statistics Hilda Maibach. The Board of Directors is led by Chairman Michael Hoffman and includes prominent industry figures such as Dr. Claudine Bruck, a former executive at GlaxoSmithKline. This leadership group provides the clinical and commercial pedigree necessary to advance buntanetap through its ongoing Phase 3 trials and toward potential New Drug Application (NDA) filings.